Interactions between Iron bisglycinate and Multiple Trace Element
1 drug interaction and 6 additional warnings found for the following 2 drugs:
- iron bisglycinate
- Multiple Trace Element (trace elements)
Drug interactions
Minor drug interactions
Minor:
zinc sulfate iron bisglycinate
Applies to: Multiple Trace Element (trace elements) and iron bisglycinate
Iron and zinc may reduce each other's absorption when they are coadministered orally. The mechanism of interaction is unknown. In clinical studies, concurrent supplementation with iron and zinc was associated with reduced efficacy in improving the growth and iron and zinc status of malnourished infants compared to supplementation with either one alone. It is not known whether the interaction occurs in adults. In any case, the clinical significance is probably minimal in healthy individuals. However, monitoring for reduced therapeutic response may be advisable in malnourished patients. Limited data suggest that the magnitude of the interaction may be lessened by separating the times of administration of each by 12 hours.
References (2)
- Lind T, Lonnerdal B, Stenlund H, et al. (2003) "A community-based randomized controlled trial of iron and zinc supplementation in Indonesian infants: interactions between iron and zinc." Am J Clin Nutr, 77, p. 883-90
- Sreedhar B (2003) "Conflicting evidence of iron and zinc interactions in humans: does iron affect zinc absorption?" Am J Clin Nutr, 78, 1226; author reply 1226-7
Food/lifestyle interactions
Moderate food/lifestyle interactions
Moderate:
iron bisglycinate Food/Lifestyle
Applies to: iron bisglycinate
Adjust dosing interval
Concomitant use of some oral medications may reduce the bioavailability of orally administered iron, and vice versa. Food taken in conjunction with oral iron supplements may reduce the bioavailability of the iron. However, in many patients intolerable gastrointestinal side effects occur necessitating administration with food.
Management
Ideally, iron products should be taken on an empty stomach (i.e., at least 1 hour before or 2 hours after meals), but if this is not possible, administer with meals and monitor the patient more closely for a subtherapeutic effect. Some studies suggest administration of iron with ascorbic acid may enhance bioavailability. In addition, administration of oral iron products and some oral medications should be separated whenever the bioavailability of either agent may be decreased. Consult the product labeling for specific separation times and monitor clinical responses as appropriate.
References (2)
- "Product Information. Feosol (ferrous sulfate)." SmithKline Beecham
- (2021) "Product Information. Accrufer (ferric maltol)." Shield Therapeutics
Disease interactions
5 potential interactions Applies to: 4 conditions, including Liver Disease, Malabsorption Syndrome, Renal Dysfunction, and Biliary Obstruction.
Biliary Obstruction
Moderate:
Multiple Trace Element
The copper sulfate and manganese sulfate in Multiple Trace Element both have a moderate potential interaction with Biliary Obstruction.
The trace elements, copper and manganese, are excreted in the bile. Copper and manganese doses may need to be adjusted, reduced, or omitted in patients with liver disease or biliary obstruction.
Liver Disease
Moderate:
Multiple Trace Element
The copper sulfate and manganese sulfate in Multiple Trace Element both have a moderate potential interaction with Liver Disease.
The trace elements, copper and manganese, are excreted in the bile. Copper and manganese doses may need to be adjusted, reduced, or omitted in patients with liver disease or biliary obstruction.
Malabsorption Syndrome
Moderate:
Multiple Trace Element
The chromic chloride hexahydrate, copper sulfate, manganese sulfate and zinc sulfate in Multiple Trace Element all have a moderate potential interaction with Malabsorption Syndrome.
The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements. GI absorption may be decreased in patients with malabsorption syndromes. Therefore, larger dosages may be required when these supplements are given orally. Parenteral administration may be appropriate.
Renal Dysfunction
Moderate:
Multiple Trace Element
The manganese sulfate in Multiple Trace Element has a moderate potential interaction with Renal Dysfunction.
Manganese sulfate and manganese chloride preparations contain aluminum and may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which also contain aluminum. Patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration. Caution is advised in patients with renal impairment, particularly in premature or neonates patients.
Moderate:
Multiple Trace Element
The chromic chloride hexahydrate and zinc sulfate in Multiple Trace Element both have a moderate potential interaction with Renal Dysfunction.
The trace metals, chromium and zinc, are excreted primarily in the urine. Selenium is partially excreted in the urine. Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.
Report options
More resources
iron bisglycinate
A total of 89 drugs are known to interact with iron bisglycinate.
- Iron bisglycinate is in the drug class iron products.
- Iron bisglycinate is used to treat the following conditions:
Multiple Trace Element
A total of 214 drugs are known to interact with Multiple Trace Element.
- Multiple trace element is in the drug class intravenous nutritional products.
- Multiple trace element is used to treat Parenteral Nutrition.
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.